Stereotaxis, Inc. (STXS) AI Stock Analysis

Stereotaxis, Inc. specializes in the design, manufacturing, and global distribution of advanced robotic systems, instruments, and information solutions for interventional cardiology and electrophysiology procedures. Founded in 1990 and based in Saint Louis, Missouri, its flagship offerings include the Genesis RMN and Niobe robotic magnetic navigation systems, which guide catheters and guidewires through cardiac vessels. The company also provides the Odyssey real-time information platform, the Stereotaxis Imaging Model S X-ray system, and disposables like the QuikCAS automated catheter advancement system, alongside magnetic ablation catheters developed with Osypka AG.

Revenue increased 20.3% to $32.4M in FY2025, up from $26.9M in FY2024 and $26.8M in FY2023, reflecting a 5-year revenue CAGR of 4.0% from FY2020. However, gross margin contracted from 66.3% in FY2021 to 52.7% in FY2025. Operating margin was -68.3% in FY2025 compared to -91.9% in FY2024, leading to a net income of -$21.6M and EPS of -$0.25. Over the trailing twelve months, revenue reached $30.1M with a net profit margin of -74.2% and EPS of -$0.24. In the latest quarter ended June 30, 2026, quarterly revenue fell 12.8% year-over-year.

As of June 30, 2026, Stereotaxis held $10.5M in cash and short-term investments against total debt of $5.2M, resulting in net cash of $5.3M. The current ratio stood at 1.42 and debt-to-equity was 0.30, with shareholders' equity of $17.5M and total assets of $55.6M. In FY2025, operating cash flow was -$13.7M and free cash flow was -$13.8M, while capital expenditures were $93,000. Additionally, the company's share count increased 32.0% over 5 years.

Stereotaxis trades at a forward P/E of 19.6x and an EV-to-EBITDA multiple of 151.4x, compared to medians of 17.3x and 12.0x, respectively, for its US-listed Healthcare peers. Its price-to-sales multiple is 3.4x, below the peer median of 4.1x. Over the past year, STXS shares fell 66.7%, lagging the S&P 500 gain of 16.8%. Over a 5-year period, the stock declined 83.0%, while the S&P 500 returned 83.0%. The stock closed at $1.01 on October 16, 2026, near its 52-week low of $1.00.

Wall Street coverage includes 2 Strong Buy and 2 Buy ratings. The mean price target is $3.00, representing a 197.0% premium over the last close of $1.01 on October 16, 2026. For the current fiscal year ending December 31, 2026, analysts forecast revenue of $34.3M and EPS of -$0.21. For the next fiscal year, 2 analysts project revenue of $45.7M and EPS of -$0.15. Stereotaxis recorded 0 EPS beats in the last 4 quarters, with the next earnings date set for November 10, 2026.

This page is an AI-written research summary of Stereotaxis, Inc. (STXS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: STXS income statement, STXS balance sheet, STXS key metrics, STXS analyst forecast, STXS chart. See the STXS stock overview for the latest quote and news.